Condition: Stage III Melanoma · Sponsor: University Hospital, Strasbourg, France
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
This description comes directly from the study's public registry record.
Cédric LENORMAND, MD · 33 3 88 11 66 27 · cedric.lenormand@chru-strasbourg.fr
Always discuss trial participation with your own doctor first.
| Service de dermatologie - Réanimation - CHU de Strasbourg - France | Strasbourg, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07302607